全球萊姆病診斷市場 - 2023-2030

概述

全球萊姆病診斷市場在 2022 年達到 16 億美元，預計到 2030 年將達到 22 億美元，2023-2030 年預測期間年複合成長率為 4.3%。

萊姆病診斷測試在血液或腦脊液 (CSF) 樣本中尋找感染跡象。腦脊液是一種透明液體，在大腦和脊髓內部及其周圍流動。該測試檢查樣本中免疫系統產生的抗體，以對抗引起萊姆病的細菌。這些診斷測試可識別免疫系統響應感染而產生的抗體。萊姆病診斷可以預測患者是否接觸受感染的黑腿蜱的可能性。

萊姆病診斷市場研究分析提供了包含定量和定性數據的市場深入展望。它根據市場細分對全球市場進行了展望和預測。它還提供全球萊姆病診斷市場規模和成長，以及到 2030 年的最新趨勢、機遇和預測。

在所有地區中，北美地區預計將在預測期內佔據全球萊姆病診斷市場的最大佔有率。北美在全球萊姆病診斷市場中佔據主導地位。血清學檢測領域在市場佔有率中佔有重要地位。

動力學

技術進步的不斷進步和新產品的推出預計將推動市場成長

全球萊姆病診斷市場的成長是由多種因素推動的，例如市場上發布的各種新創新和產品。據萊姆病協會稱，萊姆病是全球最常見的蜱傳細菌感染。市場正在見證新的經過驗證的診斷測試的推出和批准，以準確診斷萊姆病。

例如，2022 年 6 月 15 日，Adaptive Biotechnologies Corporation 是一家商業階段的生物技術公司，旨在將適應性免疫系統的遺傳學轉化為診斷和治療疾病的臨床產品，宣布推出 T-Detect Lyme。這是該公司通過其不斷壯大的 T-Detect 特許經營權提供的第二項測試。

新型產品的增加和萊姆病診斷各種產品的推出預計將促進市場成長。例如，2022 年 10 月 26 日，數位診斷公司 ixlayer 宣布將生產 CVS Health 品牌的家用樣本採集套件。 Ixlayer 的試劑盒可以檢測萊姆病、維生素 D 水平、甲狀腺功能和性傳播感染。因此，上述因素預計將推動市場成長。

不斷成長的政府舉措和對即用型診斷試劑盒的日益關注推動了市場成長

政府為預防感染而採取的更多舉措預計將推動市場成長。例如，2023 年 7 月 22 日，哈德遜河谷立法者提出的增加對抗萊姆病和蜱傳疾病資金的法案被簽署成為法律。由州參議員皮特·哈卡姆（Pete Harckham）和蘇·塞里諾（Sue Serino）以及議員迪迪·巴雷特（Didi Barrett）提出的兩黨立法旨在增加資金，以更有效地對抗傳播並更好地保護紐約人免受蜱傳疾病的侵害，該立法已由州長凱西·霍赫爾（Kathy Hochul）簽署成為法律。

對推出即用型診斷試劑盒的日益關注正在推動市場成長。例如，2023年3月21日，江蘇BioPerfectus科技有限公司發布了BioPerfectus自主研發的六款新型即時PCR試劑盒。 BioPerfectus 為我們的合作夥伴提供從樣本預處理到 PCR 擴增分析的媒介傳播疾病整體診斷解決方案，以快速應對全球衛生緊急情況。因此，政府採取的舉措可以促進市場成長。

缺乏與萊姆病診斷相關的意識預計將阻礙市場成長

對萊姆病診斷的不了解預計將阻礙預測期內市場的成長。有許多針對萊姆病的診斷測試和試劑盒，但欠已開發地區無法獲得這些測試和試劑盒。只有少數人可能知道這種疾病及其診斷。在農村地區，人們缺乏與疾病及其診斷相關的知識。

缺乏設備齊全的診斷中心無法幫助正確診斷該疾病，這可能會影響市場成長。欠已開發地區的患者無法獲得診斷測試，疾病的嚴重程度將會增加，從而影響市場成長。因此，預計市場在預測期內將下降。

目錄

第 1 章：方法和範圍

• 研究方法論
• 報告的研究目的和範圍

第 2 章：定義和概述

第 3 章：執行摘要

• 按測試類型分類
• 測試樣本片段
• 最終用戶的片段
• 按地區分類

第 4 章：動力學

• 影響因素
  • 動力
• 不斷進步的技術和新產品的推出
• 政府舉措不斷增多，對即用型診斷試劑盒的關注度不斷提高
• 限制
• 缺乏對萊姆病診斷的認知
  • 機會
  • 影響分析

第 5 章：行業分析

• 波特五力分析
• 供應鏈分析
• 定價分析
• 管道分析
• 監管分析
• 俄烏戰爭影響分析
• DMI 意見

第 6 章：COVID-19 分析

• COVID-19 分析
  • 新冠疫情爆發前的情景
  • 新冠疫情期間的情景
  • 新冠疫情后的情景
• COVID-19 期間的定價動態
• 供需譜
• 疫情期間政府與市場相關的舉措
• 製造商戰略舉措
• 結論

第 7 章：按測試類型

• 血清學檢測
• 尿抗原測試
• 淋巴細胞轉化試驗
• 免疫螢光染色
• 核酸檢測
• 其他

第 8 章：通過測試樣本

• 血
• 腦脊液
• 尿
• 其他

第 9 章：最終用戶

• 醫院
• 診斷中心
• 門診手術中心
• 公共/私人實驗室
• 醫生辦公室

第 10 章：按地區

• 北美
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 歐洲其他地區
• 南美洲
  • 巴西
  • 阿根廷
  • 南美洲其他地區
• 亞太
  • 中國
  • 印度
  • 日本
  • 澳大利亞
  • 亞太其他地區
• 中東和非洲

第 11 章：競爭格局

• 競爭場景
• 市場定位/佔有率分析
• 併購分析

第 12 章：公司簡介

• T2 Biosystems, Inc.
• 公司簡介
• 產品組合和描述
• 財務概覽
• 主要進展
• Bio-Rad Laboratories, Inc.
• Oxford Immunotec USA, Inc.
• Thermo Fisher Scientific Inc.
• Quidel Corporation
• Quest Diagnostics
• BioMerieux India Private Limited
• Diasorin SpA
• Meridian Bioscience Inc.
• Cortez Diagnostics Inc.

第 13 章：附錄

Overview

Global Lyme Disease Diagnostics Market reached US$ 1.6 billion in 2022 and is expected to reach US$ 2.2 billion by 2030, growing with a CAGR of 4.3% during the forecast period 2023-2030.

Lyme disease diagnostics tests look for signs of infection in a sample of the blood or cerebrospinal fluid (CSF). CSF is a clear liquid that flows in and around the brain and spinal cord. The test checks samples for antibodies the immune system makes to fight the bacteria that cause Lyme disease. These diagnostic tests identify the antibodies produced by the immune system in response to the infection. Lyme disease diagnostics predict the likelihood of whether the patient is exposed to infected black-legged ticks.

Lyme Disease Diagnostics Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global lyme disease diagnostics market size and growth, along with the latest trends, opportunities, and forecast till 2030.

Among all regions, the North America region is expected to hold the largest share of the global Lyme disease diagnostics market over the forecast period. North America shares a dominant position in the global Lyme disease diagnostics market. The serological test segment holds a significant position in the market share.

Dynamics

Increasing Technological Advancements and the Introduction of Novel Products are Expected to Drive Market Growth

The global Lyme disease diagnostics market growth is driven by several factors, such as various new innovations and products released in the market. According to the Lyme Disease Association, Lyme Disease is the most common tick-borne bacterial infection globally. The market is witnessing the launch and clearance of new validated diagnostic tests for accurate diagnosis of Lyme Disease.

For instance, on June 15, 2022, Adaptive Biotechnologies Corporation, a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced the launch of T-Detect Lyme. This is the company's second test to be made available from its growing T-Detect franchise.

The increase in novel launches and the introduction of various products for lyme disease diagnosis are expected to elevate the market growth. For instance, on October 26, 2022, Digital diagnostics company ixlayer announced it would produce CVS Health's branded at-home sample collection kits. Ixlayer's kits can test for Lyme disease, Vitamin D levels, thyroid function, and sexually transmitted infections. Thus, the above factors are expected to drive the market growth.

Growing Government Initiatives and Increased Focus on Ready-to-Use diagnostic Kits Drive Market Growth

The increased government initiatives in order to prevent infection are expected to drive market growth. For instance, on July 22, 2023, Hudson Valley Lawmakers' bill to bolster funding to combat Lyme and tick-borne diseases was signed into law. Bipartisan legislation advanced by State Senators Pete Harckham and Sue Serino, along with Assemblymember Didi Barrett, that aims to bolster funding to more effectively combat the spread and better protect New Yorkers against tick-borne illness has been signed into law by Governor Kathy Hochul.

The increased focus in introducing ready-to-use diagnostic kits is driving the market growth. For instance, on March 21, 2023, Jiangsu Bioperfectus Technologies Co., Ltd. has released six new Real-Time PCR Kits independently developed by BioPerfectus. BioPerfectus provides Vector-Borne Diseases Total Diagnostic Solutions from sample pre-processing to PCR amplification analysis for our partners to rapid response to a global health emergency.Thus, the initiatives taken by the government can enhance the market growth.

Lack of Awareness Associated with Lyme Disease Diagnostics is Expected to Hamper the Market Growth

Unawareness of Lyme disease diagnosis is expected to hinder the market's growth over the forecast period. A number of diagnostic tests and kits are available for lyme disease, which are not accessible by the under-developed areas. Only a few people may know about the disease and its diagnosis. In rural areas, people lack knowledge related to disease and its diagnosis.

The lack of diagnostic centers with fully equipped equipment cannot aid in the proper diagnosis of the disease, which can impact the market growth. The availability of diagnostic tests will not reach the patients in underdeveloped areas, and the severity of the disease will increase, thus impacting the market growth. Hence, the market is expected to decline over the forecast period.

Segment Analysis

The global lyme disease diagnostic market is segmented based on test type, test sample, end-user, and region.

Serological Tests Segment is Expected to Hold the Largest Market Share in the Global Lyme Disease Diagnostics Market

The global Lyme disease diagnostics market is segmented based on test type such as serological tests, urine antigen tests, lymphocytic transformation tests, immunofluorescent staining, nucleic acid tests, and others. The serological tests segment holds a dominant share over the others segments because of the presence of the identifiable number of antibodies in the blood against the pathogen. Serologic tests indicates the presence of both IgG and IgM antibodies to Borrelia burgdorferi in the blood of the individual.

The increased number of lsunches of the tests holds the segment in the dominant postion. For instance, on August 1, 2023, Incite Health, Inc., a CLIA-certified, CAP-accredited, high-complexity clinical laboratory specializing in immune system testing, announces the launch of a new paradigm in Lyme Disease testing, the ZEUS Scientific MTTT-2 ELISA system. Recently, the CDC updated its recommendation to state that serologic assays using a second ELISA test are an acceptable alternative to assays that use an immunoblot as a second test. Thus, holding the segment in the dominant position in the market share.

Geographical Penetration

North America Region Holds the Largest Market Share in the Global Lyme Disease Diagnostics Market

North America region is the dominating force in the global Lyme disease diagnostics market for the year 2022 due to the high prevalence of Lyme Disease. For instance, according to the CDC, it is estimated that approximately 476,000 people suffer Lyme disease each year in the United States, and every year, approximately 30,000 cases of Lyme disease are reported to the CDC by state health departments and the District of Columbia.

There are rising government and private institutes initiatives to treat and diagnose Lyme diseases in countries in the region. There are a majority of the companies developing Lyme disease diagnostics. Several institutes have increased their focus on developing novel diagnostic tests. Thus, the above factors are expected to drive the market growth in the region.

The increase in the government fundings is expected to drive the market growth in the region. For instance, on July 21, 2023, NIH awards announced that it will fund Post-Treatment Lyme Disease Syndrome research. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded five projects for research to understand better Post-treatment Lyme Disease Syndrome (PTLDS), which is a collection of symptoms, such as pain, fatigue, and difficulty thinking or "brain fog," which linger following standard treatment for Lyme disease. Thus, the above factors are expected to raise the region's market share.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global Lyme disease diagnostics market. As countries grappled with lockdowns, the diagnostic and treatment procedures were significantly impacted, negatively impacting the whole market.

The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting the appointments and delaying the diagnosis. The hospitals and the diagnostic centers were closed for non-essential diagnosis of the diseases. The research and new developments have been halted due to COVID-19. Thus, it has negatively impacted the Lyme disease diagnostics market.

By Test Type

• Serological Test
• Urine Antigen Tests
• Lymphocytic Transformation Test
• Immunofluorescent Staining
• Nucleic Acid Test
• Others

By Test Sample

• Blood
• Cerebrospinal Fluid
• Urine
• Others

By End-User

• Hospitals
• Diagnostic Centers
• Ambulatory Surgical Centers
• Public/Private Laboratories
• Physician's Office

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• On April 21, 2023, Moderna released new treatments for Lyme disease. Moderna has unveiled two novel mRNA vaccine candidates for Lyme disease in its development pipeline: mRNA-1982 and mRNA-1975. Lyme disease is a bacterial infection spread to humans by infected ticks, which can cause various symptoms, including a rash and a fever.

Competitive Landscape

The global Lyme disease diagnostics market is fragmented, with the presence of many local and international players. T2 Biosystems, Inc., Bio-Rad Laboratories, Inc., Oxford Immunotec USA, Inc., Thermo Fisher Scientific Inc., Quidel Corporation, Quest Diagnostics, BioMerieux India Private Limited, Diasorin S.p.A, Meridian Bioscience Inc., and Cortez Diagnostics Inc. are the leading companies with a significant market share.

Why Purchase the Report?

• To visualize the global Lyme disease diagnostic market segmentation based on test type, test sample, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of Lyme disease diagnostic market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global Lyme disease diagnostic market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Test Type
• 3.2. Snippet by Test Sample
• 3.3. Snippet by End-User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
• 4.2. Increasing technological advancements and the introduction of novel products
• 4.3. Growing Government Initiatives and Increased Focus on Ready-to-Use diagnostic Kits
• 4.4. Restraints
• 4.5. Lack of awareness associated with Lyme disease diagnostics
  • 4.5.1. Opportunity
  • 4.5.2. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Pipeline analysis
• 5.5. Regulatory Analysis
• 5.6. Russia-Ukraine War Impact Analysis
• 5.7. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Test Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 7.1.2. Market Attractiveness Index, By Test Type
• 7.2. Serological Test *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Urine Antigen Tests
• 7.4. Lymphocytic Transformation Test
• 7.5. Immunofluorescent Staining
• 7.6. Nucleic Acid Test
• 7.7. Others

8. By Test Sample

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Sample
  • 8.1.2. Market Attractiveness Index, By Test Sample
• 8.2. Blood *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Cerebrospinal Fluid
• 8.4. Urine
• 8.5. Others

9. By End-User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.1.2. Market Attractiveness Index, By End-User
• 9.2. Hospitals *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Diagnostic Centers
• 9.4. Ambulatory Surgical Centers
• 9.5. Public/Private Laboratories
• 9.6. Physician's Office

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Sample
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Sample
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. UK
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Sample
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Sample
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Sample
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. T2 Biosystems, Inc.*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Bio-Rad Laboratories, Inc.
• 12.3. Oxford Immunotec USA, Inc.
• 12.4. Thermo Fisher Scientific Inc.
• 12.5. Quidel Corporation
• 12.6. Quest Diagnostics
• 12.7. BioMerieux India Private Limited
• 12.8. Diasorin S.p.A
• 12.9. Meridian Bioscience Inc.
• 12.10. Cortez Diagnostics Inc.

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us